Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HCAR3 | P49019 | 9/20 | 0.47 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.45 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14095724 | 0.82 | KMT2A (0.37) | MAPTHCAR3 | |
| SCHEMBL4132044 | 0.80 | MAPT (0.37) | ALDH1A1MAPTHCAR3HCAR2RAB9A | |
| SCHEMBL17101820 | 0.80 | NNMT (0.45) | KDM4ESMN1; SMN2 | |
| SCHEMBL27716846 | 0.79 | HCAR3 (0.49) | ALDH1A1HSD17B10KDM4EALOX15MAPT | |
| SCHEMBL28261663 | 0.78 | RARB (0.53) | ALDH1A1HSD17B10KDM4EALOX15MAPT | |
| SCHEMBL23829753 | 0.77 | ALDH1A1 (0.47) | ALDH1A1HSD17B10KDM4EALOX15MAPT | |
| SCHEMBL20236440 | 0.77 | ALDH1A1 (0.47) | ALDH1A1HSD17B10KDM4EALOX15MAPT | |
| SCHEMBL8725910 | 0.77 | ALDH1A1 (0.47) | ALDH1A1HSD17B10KDM4EALOX15MAPT | |
| SCHEMBL5079717 | 0.77 | ALDH1A1 (0.47) | ALDH1A1HSD17B10KDM4EALOX15MAPT | |
| SCHEMBL4129784 | 0.77 | MAPK1 (0.52) | ALDH1A1KDM4EMAPTRAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840543-B2 | Compounds and uses | THE UNIVERSITY OF QUEENSLAND (AU) | 2023-12-12 | — | — | US | disclosed |
| US-11840543-B2 | Compounds and uses | THE UNIVERSITY OF QUEENSLAND (AU) | 2023-12-12 | — | — | US | disclosed |
| EP-3186224-B1 | SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS | HOFFMANN LA ROCHE (CH) | 2021-04-21 | — | — | EP | disclosed |
| EP-3174886-B1 | 2-OXA-5-AZABICYCLO[2.2.1]HEPTAN-3-YL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-02-17 | — | — | EP | disclosed |
| US-20200207780-A1 | NOVEL COMPOUNDS AND USES | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2020-07-02 | — | — | US | disclosed |
| US-10556889-B1 | Salvinorin derivatives | Blue Sky Pharmaceuticals, LLC (US) | 2020-02-11 | — | — | US | disclosed |
| CN-106661043-B | 2-oxa-5-azabicyclo [2.2.1] hept-3-yl derivatives | 豪夫迈·罗氏有限公司 | 2020-01-17 | — | — | CN | disclosed |
| CN-107001259-B | Substituted azetidine derivatives as TAAR ligands | 豪夫迈·罗氏有限公司 | 2019-12-06 | — | — | CN | disclosed |
| CN-106459073-B | 5- oxa- -2- azabicyclics [2.2.2] octyl- 4- bases and 5- oxa- -2- azabicyclics [2.2.1] hept- 4- radical derivatives as TAAR1 conditioning agents | 豪夫迈·罗氏有限公司 | 2018-11-13 | — | — | CN | disclosed |
| US-10023559-B2 | Substituted azetidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20110294781-A1 | PYRAZOLO-PYRIMIDINE COMPOUNDS | AJINOMOTO CO., INC. (JP) | 2011-12-01 | — | — | US | disclosed |
| US-20110230403-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-09-22 | — | — | US | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| WO-2010097372-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010097374-A1 | COMPOUNDS FOR USE AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7504508-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1740547-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005100321-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294781-A1 | PYRAZOLO-PYRIMIDINE COMPOUNDS | IL23R, IL2, IL17A | ALDH1A1 1291/4885HSD17B10 1051/4885KDM4E 4325/4885 |
| US-10023559-B2 | Substituted azetidine derivatives | HTR1B, MTNR1B, DRD2 | ALDH1A1 181/4885HSD17B10 2724/4885KDM4E 481/4885 |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | ALDH1A1 1599/4885HSD17B10 901/4885KDM4E 4797/4885 |
| US-10556889-B1 | Salvinorin derivatives | OPRD1, OPRK1, OPRL1 | ALDH1A1 866/4885HSD17B10 2147/4885KDM4E 4632/4885 |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | ALDH1A1 1599/4885HSD17B10 901/4885KDM4E 4797/4885 |
| US-11840543-B2 | Compounds and uses | NLRP3, NOD1, IAPP | ALDH1A1 1468/4885HSD17B10 684/4885KDM4E 3046/4885 |
| US-20110230403-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, HSD17B14 | ALDH1A1 427/4885HSD17B10 103/4885KDM4E 3630/4885 |
| US-20200207780-A1 | NOVEL COMPOUNDS AND USES | NLRP3, NOD1, GPR119 | ALDH1A1 1987/4885HSD17B10 618/4885KDM4E 3504/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | ALDH1A1 1000/4885HSD17B10 2126/4885KDM4E 4133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.